<DOC>
	<DOCNO>NCT00809302</DOCNO>
	<brief_summary>This clinical trial conduct multiple Parkinson Study Group ( PSG ) sit USA . Patients early Parkinson disease randomly allocate one 4 arm study . The 4 arm include 3 arm different dos aplindore MR tablets 1 placebo arm . The study drug take twice day ( BID ) . The study blind neither subject , investigator , know treatment subject receiving . Investigational study drug adjust assigned dosage maintain dosage balance 12 week follow-up period . The entire study take 13 week . The study assess safety tolerability aplindore measure effective aplindore improve movement effect Parkinson disease .</brief_summary>
	<brief_title>Efficacy Safety Study Aplindore Patients With Early Parkinson Disease</brief_title>
	<detailed_description>One hundred sixty eight patient randomly assign one four investigational treatment regimen outpatient study . For active treatment arm , study drug titrate assigned dosage maintain 12 week follow-up period receiving tapered dos advance study completion . Dosing take place total 13 week .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Male female least 30 year old ; Initial diagnosis idiopathic PD must within 5 year ; At least two follow cardinal sign must present : bradykinesia , rest tremor , rigidity ; PD progression must Stage 1 2.5 ( inclusive ) accord modify Hoehn Yahr classification system ; Have score MoCA least 26 ; Have score Beck Depression Inventory II ( BDI II ) less 15 ; Have screen UPDRS ( Part III ) motor score least 10 ; In good general health determine thorough medical history physical examination ( include vital sign ) , neurological examination , 12lead ECG , clinical chemistry laboratory test ; Females childbearing potential must use acceptable method contraception negative serum pregnancy test screen baseline visit . Acceptable method contraception oral , intrauterine , implantable , injectable contraceptive , double barrier method condom impregnate spermicide . After screen , subject use oral contraceptive method contraception must agree add additional method 30 day last dose study medication . Women oral contraceptive use cervical ring must use least 1 month screen visit ; Male subject partner childbearing potential must use adequate contraception study 3 month study ; Females receive hormone replacement therapy must stable regimen least 3 month ; Able read , understand , provide written/dated informed consent enrol study , must willing comply study procedure . History clinical feature consistent atypical parkinsonian syndrome ; History surgical intervention PD ; History severe allergic anaphylactic reaction drug ; History allergy know sensitivity , hypersensitivity , severe adverse reaction ( e.g. , require abrupt discontinuation ) drug similar aplindore ; Taking prescription drug therapy counter medication chronic medical condition stable dos least 1 month screen visit ; Treated Ldopa within 2 month baseline visit cumulative treatment exceed 2 month ; Have take dopamine agonist therapy within 1 month baseline visit take dopamine agonist therapy cumulative period exceed 2 month ; Are receive amantadine , anticholinergic , monoamine oxidase B inhibitor take stable dos least 2 month baseline visit ; A clinically significantly abnormal clinical laboratory value judge investigator value disapprove study Clinical Monitor ; A decrease either systolic blood pressure least 40 mmHg decrease diastolic blood pressure least 20 mmHg follow 5 minute supine 2 minute stand , within 6 month baseline visit ; Clinically significant ECG finding , include prolonged QTcF interval ( &gt; 450 msec men , &gt; 470 msec woman ) ; Evidence clinically significant unstable allergic ( except untreated , asymptomatic , seasonal allergy time dose ) , hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurological disease ; History basal squamous cell skin cancer carcinoma situ cervix within 2 year screen visit exclude ; cancer diagnose , subject history within 5 year screen visit exclude ; Any condition may significantly affect drug absorption ; Pregnant lactating female ; History evidence drug abuse alcoholism define DSMIV TR within 12 month baseline visit evidence current withdrawal drug alcohol baseline visit ; Prior exposure aplindore ; Received investigational drug within 60 day baseline visit .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>